Portal de Periódicos da CAPES

STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers

2016; Impact Journals LLC; Volume: 7; Issue: 6 Linguagem: Inglês

10.18632/oncotarget.6855

1949-2553

Jae‐Sung Kim, Hyun‐Ah Kim, Min-Ki Seong, Hyesil Seol, Jeong Su Oh, Eun‐Kyu Kim, Jong Wook Chang, Sang‐Gu Hwang, Woo Chul Noh,

Lung Cancer Treatments and Mutations

Although radiotherapy resistance is associated with locoregional recurrence and distant metastasis in breast cancers, clinically relevant molecular markers and critical signaling pathways of radioresistant breast cancer are yet to be defined. Herein, we show that HER2-STAT3-survivin regulation is associated with radiotherapy resistance in HER2-positive breast cancers. Depletion of HER2 by siRNA sensitized HER2-positive breast cancer cells to irradiation by decreasing STAT3 activity and survivin, a STAT3 target gene, expression in HER2-positive breast cancer cells. Furthermore, inhibition of STAT3 activation or depletion of survivin also sensitized HER2-positive breast cancer cells to irradiation, suggesting that the HER2-STAT3-survivin axis is a key pathway in radiotherapy resistance of HER2-positive breast cancer cells. In addition, our clinical analysis demonstrated the association between HER2-positive breast cancers and radiotherapy resistance. Notably, we found that increased expression of phosphorylated STAT3, STAT3, and survivin correlated with a poor response to radiotherapy in HER2-positive breast cancer tissues. These findings suggest that the HER2-STAT3-survivin axis might serve as a predictive marker and therapeutic target to overcome radiotherapy resistance in HER2-positive breast cancers.